Mirvaso

Mirvaso

brimonidine

Manufacturer:

Galderma

Distributor:

Forewide
/
DCH Auriga - Healthcare
Concise Prescribing Info
Contents
Brimonidine
Indications/Uses
Symptomatic treatment of facial erythema of rosacea in adult patients.
Dosage/Direction for Use
1 application/24 hr, at any time suitable for the patient, for as long as facial erythema is present. Max daily recommended dose: 1 g of gel in total wt, divided into 5 pea size amounts.
Contraindications
Hypersensitivity. Patients receiving MAOIs (eg, selegiline or moclobemide) & tricyclic (eg, imipramine) or tetracyclic (eg, maprotiline, mianserin or mirtazapin) antidepressants. Childn <2 yr.
Special Precautions
Do not apply on irritated skin (including following laser therapy) or open wounds. Discontinue in case of severe irritation or contact allergy; aggravated erythema or flushing. Do not apply close to the eyes. Renal or hepatic impairment. Avoid any increase in the daily amount applied &/or frequency of daily application. Concomitant use w/ other systemic α-adrenergic agonists may potentiate adverse reactions in patients w/ severe or unstable or uncontrolled CV disease; depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma or Sjörgen's syndrome. May cause allergic reactions due to methylparahydroxybenzoate (E218) & skin irritation to propylene glycol. Pregnancy & lactation. Should not be used in childn or adolescents 2-18 yr. Limited study on elderly >65 yr.
Adverse Reactions
Flushing, erythema, pruritus, skin burning sensation, pallor at the application site.
Drug Interactions
Contraindicated in patients receiving MAOIs, tricyclic or tetracyclic antidepressants. Possible additive or potentiating effect w/ CNS depressants. Caution when taking substances which affect the metabolism & uptake of circulating amines eg, chlorpromazine, methylphenidate, reserpine. May interact w/ or interfere w/ activity of α-adrenergic receptors (eg, isoprenaline, prazosin). May cause clinically insignificant decreases in BP w/ antihypertensives &/or cardiac glycosides.
MIMS Class
Topical Antihistamines/Antipruritics
ATC Classification
D11AX21 - brimonidine ; Belongs to the class of other dermatologicals.
Presentation/Packing
Form
Mirvaso topical gel 3 mg/g
Packing/Price
10 g x 1's;30 g x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in